Josipa Bilic

Josipa Bilic

Auto-generated profile, based on publicly available information

Josipa Bilic

Vall d'Hebron Institute of Research, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2008 in Nature Biotechnology
Verified
Journal Article
Closed access
Trond AasenTrond Aasen
Trond Aasen
Angel RayaAngel Raya
Angel Raya
MBMaria J. Barrero
Maria J. Barrero
EGElena Garreta
Elena Garreta
ACAntonella Consiglio
Antonella Consiglio
JBJuan Carlos Izpisúa Belmonte
Juan Carlos Izpisúa Belmonte

15 June 2007 in Science
Verified
Journal Article
Closed access
PDF file
JBJosipa Bilić
Josipa Bilić
YHYa-Lin Huang
Ya-Lin Huang
GDGary Davidson
Gary Davidson
TZTimo Zimmermann
Timo Zimmermann
CCCristina-Maria Cruciat
Cristina-Maria Cruciat
CNChristof Niehrs
Christof Niehrs
Multiple signaling pathways, including Wnt signaling, participate in animal development, stem cell biology, and human cancer. Although many components of the Wnt pathway have been identified, unresolved questions remain as to the mechanism by which Wnt binding to its receptors Frizzled and Low-density lipoprotein receptor–related protein 6 (LRP6) triggers downstream signaling events. With live imaging of vertebrate cells, we show that Wnt treatment quickly induces plasma membrane–associated LRP6 aggregates. LRP6 aggregates are phosphorylated and can be detergent-solubilized as ribosome-sized multiprotein complexes. Phospho-LRP6 aggregates contain Wnt-pathway components but no common vesicular traffic markers except caveolin. The scaffold protein Dishevelled (Dvl) is required for LRP6 phosphorylation and aggregation. We propose that Wnts induce coclustering of receptors and Dvl in LRP6-signalosomes, which in turn triggers LRP6 phosphorylation to promote Axin recruitment and β-catenin stabilization.

1 December 2005 in Nature
Verified
Journal Article
Closed access
GDGary Davidson
Gary Davidson
WWWei Wu
Wei Wu
JSJinlong Shen
Jinlong Shen
JBJosipa Bilic
Josipa Bilic
UFUrsula Fenger
Ursula Fenger
CNChristof Niehrs
Christof Niehrs


18 September 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SRSergio Ruiz
Sergio Ruiz
DDDinh Diep
Dinh Diep
AGAthurva Gore
Athurva Gore
APAthanasia D. Panopoulos
Athanasia D. Panopoulos
NMNuria Montserrat
Nuria Montserrat
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte
Generation of human induced pluripotent stem cells (hiPSCs) by the expression of specific transcription factors depends on successful epigenetic reprogramming to a pluripotent state. Although hiPSCs and human embryonic stem cells (hESCs) display a similar epigenome, recent reports demonstrated the persistence of specific epigenetic marks from the somatic cell type of origin and aberrant methylation patterns in hiPSCs. However, it remains unknown whether the use of different somatic cell sources, encompassing variable levels of selection pressure during reprogramming, influences the level of epigenetic aberrations in hiPSCs. In this work, we characterized the epigenomic integrity of 17 hiPSC lines derived from six different cell types with varied reprogramming efficiencies. We demonstrate that epigenetic aberrations are a general feature of the hiPSC state and are independent of the somatic cell source. Interestingly, we observe that the reprogramming efficiency of somatic cell lines inversely correlates with the amount of methylation change needed to acquire pluripotency. Additionally, we determine that both shared and line-specific epigenetic aberrations in hiPSCs can directly translate into changes in gene expression in both the pluripotent and differentiated states. Significantly, our analysis of different hiPSC lines from multiple cell types of origin allow us to identify a reprogramming-specific epigenetic signature comprised of nine aberrantly methylated genes that is able to segregate hESC and hiPSC lines regardless of the somatic cell source or differentiation state.

21 November 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
PRPaulo Rodrigues
Paulo Rodrigues
IMIrati Macaya
Irati Macaya
SBSarah Bazzocco
Sarah Bazzocco
RMRocco Mazzolini
Rocco Mazzolini
EAElena Andretta
Elena Andretta
Diego ArangoDiego Arango
Diego Arango
Activation of the small GTPase RHOA has strong oncogenic effects in many tumour types, although its role in colorectal cancer remains unclear. Here we show that RHOA inactivation contributes to colorectal cancer progression/metastasis, largely through the activation of Wnt/β-catenin signalling. RhoA inactivation in the murine intestine accelerates the tumorigenic process and in human colon cancer cells leads to the redistribution of β-catenin from the membrane to the nucleus and enhanced Wnt/β-catenin signalling, resulting in increased proliferation, invasion and de-differentiation. In mice, RHOA inactivation contributes to colon cancer metastasis and reduced RHOA levels were observed at metastatic sites compared with primary human colon tumours. Therefore, we have identified a new mechanism of activation of Wnt/β-catenin signalling and characterized the role of RHOA as a novel tumour suppressor in colorectal cancer. These results constitute a shift from the current paradigm and demonstrate that RHO GTPases can suppress tumour progression and metastasis.